<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34007201-2d47-96fd-e063-6394a90a6327"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ZELVYSIA safely and effectively.
 <br/>
See full prescribing information for ZELVYSIA.
 <br/>
      <br/>
ZELVYSIA 
 <sup>TM</sup> (sapropterin dihydrochloride) powder, for oral solution
 <br/>
Initial U.S. Approval: 2007
</title>
   <effectiveTime value="20250430"/>
   <setId root="8de84882-dd24-46f2-8416-5e492d4275d1"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="016894249"/>
            <name>Aucta Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="016894249"/>
                  <name>Aucta Pharmaceuticals, Inc.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3405e8a1-b46f-853a-e063-6294a90a288a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250430"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73289-0070" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZELVYSIA</name>
                        <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>SAPROPTERIN DIHYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RG277LF5B3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SAPROPTERIN DIHYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="EGX657432I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SAPROPTERIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="73289-0070-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73289-0070-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250429"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA218645" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250429"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>off-white to yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73289-0071" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZELVYSIA</name>
                        <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sapropterin dihydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RG277LF5B3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SAPROPTERIN DIHYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="EGX657432I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SAPROPTERIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="73289-0071-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73289-0071-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250429"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA218645" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250429"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>off-white to yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_534089da-4209-499d-a0f0-d5c9dac7fcbb">
               <id root="34007201-2d48-96fd-e063-6394a90a6327"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Zelvysia is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Zelvysia is to be used in conjunction with a Phe-restricted diet.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Zelvysia is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU). Zelvysia is to be used in conjunction with a Phe‑restricted diet. (
 
    <linkHtml href="#LINK_534089da-4209-499d-a0f0-d5c9dac7fcbb">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_d42af50d-f628-4cf7-8040-8a037b87204e">
               <id root="34007201-2d49-96fd-e063-6394a90a6327"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>All patients with PKU who are being treated with Zelvysia should also be treated with a Phe-restricted diet, including dietary protein and Phe restriction.  (
 
    <linkHtml href="#LINK_de73bad0-e4e5-4fd9-a9c0-b7b47e8faf3f">2.1</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Starting Dosage</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="italics">Pediatric patients 1 month to 6 years:</content>The recommended starting dosage of Zelvysia is 10 mg/kg administered orally once daily. (
  
     <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="italics">Patients 7 years and older</content>: The recommended starting dosage of Zelvysia is 10 to 20 mg/kg administered orally once daily. (
  
     <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Dosage Adjustment</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Doses of Zelvysia may be adjusted in the range of 5 to 20 mg/kg taken once daily. (
  
     <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>)
 
    </item>
                           <item>Monitor blood Phe regularly, especially in pediatric patients. (
  
     <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>,
  
     <linkHtml href="#LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">5.3</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Preparation and Administration</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>See the full prescribing information for preparation and administration instructions. (
  
     <linkHtml href="#S2.3">2.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_de73bad0-e4e5-4fd9-a9c0-b7b47e8faf3f">
                     <id root="34007201-2d4a-96fd-e063-6394a90a6327"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1Recommendations Prior to Zelvysia Treatment</title>
                     <text>
                        <paragraph>Treatment with Zelvysia should be directed by physicians knowledgeable in the management of PKU.</paragraph>
                        <paragraph>All patients with PKU who are being treated with  Zelvysia should also be treated with a Phe-restricted diet, including dietary protein and Phe restriction.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_afba740c-6d56-4676-9532-052b8316c37f">
                     <id root="34007201-2d4b-96fd-e063-6394a90a6327"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Recommended Dosage and Administration</title>
                     <text>
                        <paragraph>The recommended starting dosage of Zelvysia is:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients 1 month to 6 years</content>: 10 mg/kg (actual body weight) administered orally once daily.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients 7 years and older</content>: 10 to 20 mg/kg (actual body weight) administered orally once daily.

 </paragraph>
                        <paragraph>Administer Zelvysia with a meal, preferably at the same time each day
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_022144f9-e6a6-4de9-87c6-65867107caa6">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>A missed dose should be administered as soon as possible, but two doses should not be administered on the same day.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="34007201-2d4c-96fd-e063-6394a90a6327"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Evaluation Period</content>
                              </paragraph>
                              <paragraph>Existing dietary protein and Phe intake should not be modified during the evaluation period.</paragraph>
                              <paragraph>If a 10 mg/kg per day starting dose is used, then response to therapy is determined by change in blood Phe following treatment with Zelvysia at 10 mg/kg per day for a period of up to 1 month. Blood Phe levels should be checked after 1 week of Zelvysia treatment and periodically for up to a month. If blood Phe does not decrease from baseline at 10 mg/kg per day, the dose may be increased to 20 mg/kg per day. Patients whose blood Phe does not decrease after 1 month of treatment at 20 mg/kg per day do not show a biochemical response and treatment with Zelvysia should be discontinued in these patients.</paragraph>
                              <paragraph>If a 20 mg/kg per day starting dose is used, then response to therapy is determined by change in blood Phe following treatment with Zelvysia at 20 mg/kg per day for a period of 1 month. Blood Phe levels should be checked after 1 week of Zelvysia treatment and periodically during the first month. Treatment should be discontinued in patients who do not show a biochemical response (blood Phe does not decrease) after 1 month of treatment at 20 mg/kg per day
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_cbb9c000-cfae-4314-8428-28033fc2c327">5.4</linkHtml>)]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34007201-2d4d-96fd-e063-6394a90a6327"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Adjustment</content>
                              </paragraph>
                              <paragraph>Once responsiveness to Zelvysia has been established, the dosage may be adjusted within the range of 5 to 20 mg/kg per day according to biochemical response to therapy (blood Phe). Periodic blood Phe monitoring is recommended to assess blood Phe control, especially in pediatric patients
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="34007201-2d4e-96fd-e063-6394a90a6327"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation and Administration Instructions</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="34007201-2d4f-96fd-e063-6394a90a6327"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text/>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34007201-2d50-96fd-e063-6394a90a6327"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Zelvysia Powder for Oral Solution</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="34007201-2d51-96fd-e063-6394a90a6327"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients weighing greater than 10 kg</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Zelvysia powder for oral solution should be dissolved in 120 to 240 mL of water or apple juice and taken orally within 30 minutes of dissolution.</item>
                                       <item>Zelvysia powder for oral solution may also be stirred in a small amount of soft food such as apple sauce or pudding.</item>
                                       <item>Empty the contents of the packet(s) in water, apple juice, or a small amount of soft foods and mix thoroughly. The powder should dissolve completely.</item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="34007201-2d52-96fd-e063-6394a90a6327"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients weighing 10 kg or less (use 100 mg packets)</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>For infants weighing 10 kg or less, Zelvysia powder for oral solution can be dissolved in as little as 5 mL of water or apple juice and a portion of this solution corresponding to a 10 mg/kg dose may be administered orally via an oral dosing syringe.</item>
                                       <item>Table 1 provides dosing information for infants at the recommended starting dose of 10 mg/kg per day.</item>
                                       <item>Refer to Table 2 for dosing information at 20 mg/kg per day if dosage adjustment is needed.</item>
                                    </list>
                                    <paragraph>
                                       <content styleCode="bold">Table 1: 10 mg/kg per day Dosing Table for Infants Weighing 10 kg or Less</content>
                                    </paragraph>
                                    <table width="515.22px">
                                       <col/>
                                       <col/>
                                       <col/>
                                       <col/>
                                       <col/>
                                       <thead>
                                          <tr>
                                             <td align="center" rowspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Patient</paragraph>
                                                <paragraph>Weight (kg)</paragraph>
                                             </td>
                                             <td align="center" colspan="4" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Starting Dose: 10 mg/kg per day*</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Dose (mg)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Zelvysia Powder for Oral Solution </paragraph>
                                                <paragraph> 100 mg Packets Dissolved
     
      <sup>†</sup>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Dilution Volume 
      <br/>  (mL)
     
      <sup>‡</sup>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Administered Dose volume</paragraph>
                                                <paragraph>(mL)
     
      <sup>§</sup>
                                                </paragraph>
                                             </td>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph> 1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>20</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph> 2</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  3</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>30</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph> 3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>40</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph> 4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>50</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph> 5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  6</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>60</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph> 3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>70</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  3.5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  8</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>80</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph> 4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  9</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>90</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>4.5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>100</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>*Starting dose for infants is 10 mg/kg per day. Dosing information for 20 mg/kg per day is provided in Table 2.</paragraph>
                                    <paragraph>
                                       <sup>†</sup>Powder for oral solution provided in single use packets containing 100 mg sapropterin dihydrochloride per packet.

 </paragraph>
                                    <paragraph>
                                       <sup>‡</sup>Volume of water or apple juice to dissolve Zelvysia Powder for Oral Solution.

 </paragraph>
                                    <paragraph>
                                       <sup>§</sup>Discard remainder of mixture after volume to be administered is drawn.

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold"> </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Table 2: 20 mg/kg per day Dosing Table for Infants Weighing 10 kg or Less</content>
                                    </paragraph>
                                    <table width="520.44px">
                                       <col/>
                                       <col width="52.9pt"/>
                                       <col width="53.55pt"/>
                                       <col/>
                                       <col/>
                                       <thead>
                                          <tr>
                                             <td align="center" rowspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Patient</paragraph>
                                                <paragraph>Weight (kg)</paragraph>
                                             </td>
                                             <td align="center" colspan="4" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>20 mg/kg per day</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Dose (mg)</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Zelvysia Powder for Oral Solution </paragraph>
                                                <paragraph> 100 mg Packets
     
      <sup>* </sup>Dissolved
    
     </paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Dilution Volume 
      <br/>  (mL)
     
      <sup>†</sup>
                                                </paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                                <paragraph>Administered 
      <br/>  Dose volume
     </paragraph>
                                                <paragraph>(mL)
     
      <sup>§</sup>
                                                </paragraph>
                                             </td>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  20</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  1</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  40</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  2</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  3</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  60</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  4</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  80</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>100</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>1</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  6</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>120</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  3</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  7</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>140</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  3.5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  8</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>160</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  4</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  9</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>180</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>  4.5</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>10</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>200</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>2</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                             <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                                <paragraph>5</paragraph>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>
                                       <sup>*</sup>Powder for oral solution provided in single use packets containing 100 mg sapropterin dihydrochloride per packet.

 </paragraph>
                                    <paragraph>
                                       <sup>†</sup>Volume of water or apple juice to dissolve Zelvysia Powder for Oral Solution.

 </paragraph>
                                    <paragraph>
                                       <sup>§</sup>Discard remainder of mixture after volume to be administered is drawn.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c81380ce-6c84-4f34-8cac-f01f35c1757b">
               <id root="34007201-2d53-96fd-e063-6394a90a6327"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Zelvysia powder for oral solution is available as a unit dose packet containing 100 mg of sapropterin dihydrochloride and as a unit dose packet containing 500 mg of sapropterin dihydrochloride. The powder is off-white to yellow in color.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Powder for Oral Solution: 100 mg and 500 mg sapropterin dihydrochloride. (
  
     <linkHtml href="#LINK_c81380ce-6c84-4f34-8cac-f01f35c1757b">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8c8c8ac9-9e97-4ca4-b614-6f251d80e625">
               <id root="34007201-2d54-96fd-e063-6394a90a6327"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20240831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (
 
    <linkHtml href="#LINK_8c8c8ac9-9e97-4ca4-b614-6f251d80e625">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_27cf67d6-8b91-4f0a-b81a-614b49e6c714">
               <id root="34007201-2d55-96fd-e063-6394a90a6327"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Hypersensitivity Reactions Including Anaphylaxis</content>: Zelvysia is not recommended in patients with a history of anaphylaxis to Zelvysia ; discontinue treatment in patients who experience anaphylaxis and initiate appropriate medical treatment. Continue dietary Phe restrictions. (
   
      <linkHtml href="#LINK_165d2049-b757-476c-8ced-b0653cefe9ef">5.1</linkHtml>)
  
     </paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Upper Gastrointestinal Mucosal Inflammation</content>: Monitor patients for signs and symptoms of these conditions including esophagitis and gastritis. (
   
      <linkHtml href="#LINK_f57f3981-43e3-462b-92c9-d54de0ce2b19">5.2</linkHtml>)
  
     </paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Hypophenylalaninemia</content>: Pediatric patients younger than 7 years treated with Zelvysia doses of 20 mg/kg per day are at increased risk for low levels of blood Phe compared with patients 7 years and older. (
   
      <linkHtml href="#LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">5.3</linkHtml>)
  
     </paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Monitoring Blood Phe Levels During Treatment</content>: Ensure adequate blood Phe control and nutritional balance during treatment with Zelvysia .  Frequent blood monitoring is recommended, especially in pediatric patients. (
   
      <linkHtml href="#LINK_cbb9c000-cfae-4314-8428-28033fc2c327">5.4</linkHtml>,
   
      <linkHtml href="#LINK_de73bad0-e4e5-4fd9-a9c0-b7b47e8faf3f">2.1</linkHtml>)
  
     </paragraph>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Lack of Biochemical Response to Sapropterin Dihydrochloride</content>
                                 <content styleCode="underline">T</content>
                                 <content styleCode="underline">reatment</content>:  Response to sapropterin dihydrochloride treatment cannot be pre-determined by laboratory (e.g., molecular) testing and can only be determined by a therapeutic trial of sapropterin dihydrochloride . (
   
      <linkHtml href="#LINK_78f267d6-30ae-4528-b5e4-dd15f8ba91de">5.5</linkHtml>,
   
      <linkHtml href="#LINK_de73bad0-e4e5-4fd9-a9c0-b7b47e8faf3f">2.1</linkHtml>)
  
     </paragraph>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Interaction with Levodopa</content>: Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (
   
      <linkHtml href="#LINK_d4553275-042f-4882-9ae7-ae42261c05a6">5.6</linkHtml>,
   
      <linkHtml href="#LINK_2df07890-a1a0-432e-a6d5-58a9438f8c51">7</linkHtml>)
  
     </paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Hyperactivity</content>: Monitor patients for hyperactivity. (
   
      <linkHtml href="#LINK_d6488aff-30d8-49e7-8bed-fe7f53f497de">5.7</linkHtml>)
  
     </paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_165d2049-b757-476c-8ced-b0653cefe9ef">
                     <id root="34007201-2d56-96fd-e063-6394a90a6327"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.1 Hypersensitivity Reactions Including Anaphylaxis</title>
                     <text>
                        <paragraph>Sapropterin dihydrochloride is not recommended in patients with a history of anaphylaxis to sapropterin dihydrochloride . Hypersensitivity reactions, including anaphylaxis and rash, have occurred
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#LINK_c475d61d-278a-4fd5-a44c-7bdbd83fea45">6.2</linkHtml>)]
 
  </content>. Signs of anaphylaxis include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. Discontinue treatment with sapropterin dihydrochloride in patients who experience anaphylaxis and initiate appropriate medical treatment. Continue dietary protein and Phe restriction in patients who experience anaphylaxis.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f57f3981-43e3-462b-92c9-d54de0ce2b19">
                     <id root="34007201-2d57-96fd-e063-6394a90a6327"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.2 Upper Gastrointestinal Mucosal Inflammation</title>
                     <text>
                        <paragraph>Gastrointestinal (GI) adverse reactions suggestive of upper GI mucosal inflammation have been reported with sapropterin dihydrochloride .  Serious adverse reactions included esophagitis and gastritis
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#LINK_c475d61d-278a-4fd5-a44c-7bdbd83fea45">6.2</linkHtml>)]
 
  </content>. If left untreated, these could lead to severe sequelae including esophageal stricture, esophageal ulcer, gastric ulcer, and bleeding and such complications have been reported in patients receiving sapropterin dihydrochloride . Monitor patients for signs and symptoms of upper GI mucosal inflammation.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">
                     <id root="34007201-2d58-96fd-e063-6394a90a6327"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.3 Hypophenylalaninemia</title>
                     <text>
                        <paragraph>In clinical trials of sapropterin dihydrochloride , some PKU patients experienced hypophenylalaninemia (low blood Phe) during treatment with sapropterin dihydrochloride .  In a clinical study of pediatric patients younger than 7 years old treated with sapropterin dihydrochloride 20 mg/kg per day, the incidence of hypophenylalaninemia was higher than in clinical trials of older patients
 
  <content styleCode="italics">  [see Adverse Reactions (
  
   <linkHtml href="#LINK_19984302-67d2-4695-8192-69303591d8c1">6.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cbb9c000-cfae-4314-8428-28033fc2c327">
                     <id root="34007201-2d59-96fd-e063-6394a90a6327"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.4 Monitoring Blood Phe Levels During Treatment</title>
                     <text>
                        <paragraph>Prolonged elevations of blood Phe levels in patients with PKU can result in severe neurologic damage, including severe intellectual disability, developmental delay, microcephaly, delayed speech, seizures, and behavioral abnormalities. Conversely, prolonged levels of blood Phe that are too low have been associated with catabolism and endogenous protein breakdown, which has been associated with adverse developmental outcomes. Active management of dietary Phe intake while taking sapropterin dihydrochloride is required to ensure adequate Phe control and nutritional balance. Monitor blood Phe levels during treatment to ensure adequate blood Phe level control. Frequent blood monitoring is recommended in the pediatric population
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_78f267d6-30ae-4528-b5e4-dd15f8ba91de">
                     <id root="34007201-2d5a-96fd-e063-6394a90a6327"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.5 Lack of Biochemical Response to Sapropterin Dihydrochloride</title>
                     <text>
                        <paragraph>Some patients with PKU do not show biochemical response (reduction in blood Phe) with treatment with sapropterin dihydrochloride . In two clinical trials at a sapropterin dihydrochloride dose of 20 mg/kg per day, 56% to 75% of pediatric PKU patients showed a biochemical response to sapropterin dihydrochloride , and in one clinical trial at a dose of 10 mg/kg per day, 20% of adult and pediatric PKU patients showed a biochemical response to sapropterin dihydrochloride
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#LINK_a78d7a8a-ecb7-4b13-a545-85abb8200bcf">14</linkHtml>)]
 
  </content>. 

 </paragraph>
                        <paragraph>Biochemical response to sapropterin dihydrochloride treatment cannot generally be pre-determined by laboratory testing (e.g., molecular testing), and should be determined through a therapeutic trial (evaluation) of sapropterin dihydrochloride response
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d4553275-042f-4882-9ae7-ae42261c05a6">
                     <id root="34007201-2d5b-96fd-e063-6394a90a6327"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.6 Interaction with Levodopa</title>
                     <text>
                        <paragraph>In a 10-year post-marketing safety surveillance program for a non-PKU indication using another sapropterin product, 3 patients with underlying neurological disorders experienced seizures, exacerbation of seizures, over-stimulation, and irritability during co-administration of levodopa and sapropterin. Monitor patients who are receiving levodopa for changes in neurological status during treatment with sapropterin dihydrochloride
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#LINK_2df07890-a1a0-432e-a6d5-58a9438f8c51">7</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d6488aff-30d8-49e7-8bed-fe7f53f497de">
                     <id root="34007201-2d5c-96fd-e063-6394a90a6327"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Hyperactivity</title>
                     <text>
                        <paragraph>In the sapropterin dihydrochloride postmarketing safety surveillance program, 2 patients with PKU experienced hyperactivity when treated with sapropterin dihydrochloride
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#LINK_c475d61d-278a-4fd5-a44c-7bdbd83fea45">6.2</linkHtml>)]
 
  </content>. Monitor patients for hyperactivity.

 </paragraph>
                        <paragraph>
                           <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0ac0d1ce-4568-424c-a492-db4a179aae7d">
               <id root="34007201-2d5d-96fd-e063-6394a90a6327"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS</title>
               <text/>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥4%) are: headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion. (
 
    <linkHtml href="#LINK_19984302-67d2-4695-8192-69303591d8c1">6.1</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact contact Aucta Pharmaceuticals, Inc. at 1-800-655-9902 , or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">www.fda.gov/medwatch</content>
                           <content styleCode="bold">
                              <content styleCode="italics">. 
      <br/>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_19984302-67d2-4695-8192-69303591d8c1">
                     <id root="34007201-2d5e-96fd-e063-6394a90a6327"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </paragraph>
                        <paragraph>
                           <content styleCode="underline">PKU Clinical Studies</content>
                        </paragraph>
                        <paragraph>The safety of sapropterin dihydrochloride was evaluated in 7 clinical studies in patients with PKU (aged 1 month to 50 years)
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#LINK_a78d7a8a-ecb7-4b13-a545-85abb8200bcf">14</linkHtml>)]
 
  </content>. 

 </paragraph>
                        <paragraph>In Studies 1-4 (controlled and uncontrolled studies), 579 patients with PKU aged 4 to 49 years received sapropterin dihydrochloride in doses ranging from 5 to 20 mg/kg per day for lengths of treatment ranging from 1 to 164 weeks. The patient population was evenly distributed in gender, and approximately 95% of patients were Caucasian. The most common adverse reactions (≥4% of patients) were headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion.</paragraph>
                        <paragraph>The data described in Table 3 reflect exposure of 74 patients with PKU to sapropterin dihydrochloride at doses of 10 to 20 mg/kg per day for 6 to 10 weeks in two double-blind, placebo-controlled clinical trials (Studies 2 and 4).</paragraph>
                        <paragraph>Table 3 enumerates adverse reactions occurring in at least 4% of patients treated with sapropterin dihydrochloride in the double-blind, placebo-controlled clinical trials described above.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3: Summary of Adverse Reactions Occurring in ≥4% of Patients in Placebo-Controlled Clinical Studies with Sapropterin Dihydrochloride</content>
                        </paragraph>
                        <table>
                           <col width="167.8pt"/>
                           <col/>
                           <col width="98.4pt"/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">MedDRA Preferred Term</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Treatment</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Sapropterin Dihydrochloride</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=74)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=59)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top"/>
                                 <td>
                                    <paragraph>No. Patients (%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>No. Patients (%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>11 (15)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>8 (14)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Rhinorrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>8 (11)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Pharyngolaryngeal pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>7 (10)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>6 (8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>6 (8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>4 (7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Cough</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>5 (7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Nasal congestion</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>3 (4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In open-label, uncontrolled clinical trials (Studies 1 and 3) all patients received sapropterin dihydrochloride in doses of 5 to 20 mg/kg per day, and adverse reactions were similar in type and frequency to those reported in the double-blind, placebo-controlled clinical trials
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#LINK_a78d7a8a-ecb7-4b13-a545-85abb8200bcf">14</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>In Study 5, 65 pediatric patients with PKU aged 1 month to 6 years received sapropterin dihydrochloride 20 mg/kg per day for 6 months. Adverse reactions in these patients were similar in frequency and type as those seen in other sapropterin dihydrochloride clinical trials except for an increased incidence of low Phe levels. Twenty-five percent (16 out of 65) of patients developed Phe levels below normal for age
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">5.3</linkHtml>), Use In Specific Populations (
  
   <linkHtml href="#LINK_4e1cde41-766f-4fd7-98be-b0b8ff457b6b">8.4</linkHtml>), and Clinical Studies (
  
   <linkHtml href="#LINK_a78d7a8a-ecb7-4b13-a545-85abb8200bcf">14</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>In Study 6, a long term, open-label, extension study of 111 patients aged 4 to 50 years, receiving sapropterin dihydrochloride in doses ranging from 5 to 20 mg/kg per day, adverse reactions were similar in type and frequency to those reported in the previous clinical studies. Fifty-five patients received sapropterin dihydrochloride both as dissolved and intact tablets. There were no notable differences in the incidence or severity of adverse reactions between the two methods of administration. The mean (± SD) exposure to sapropterin for the entire study population was 659 ± 221 days (maximum 953 days).</paragraph>
                        <paragraph>In Study 7, 27 pediatric patients with PKU aged 0 to 4 years received sapropterin dihydrochloride 10 mg/kg per day or 20 mg/kg per day. Adverse reactions were similar in type and frequency to those observed in other clinical trials, with the addition of rhinitis, which was reported in 2 subjects (7.4%). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Safety Experience from Clinical Studies for Non-PKU Indications</content>
                        </paragraph>
                        <paragraph>Approximately 800 healthy subjects and patients with disorders other than PKU, some of whom had underlying neurologic disorders or cardiovascular disease, have been administered a different formulation of the same active ingredient (sapropterin) in approximately 19 controlled and uncontrolled clinical trials. In these clinical trials, subjects were administered sapropterin at doses ranging from 1 to 100 mg/kg per day for lengths of exposure from 1 day to 2 years. Serious and severe adverse reactions (regardless of causality) during sapropterin administration were seizures, exacerbation of seizures
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">5.3</linkHtml>)]
 
  </content>, dizziness, gastrointestinal bleeding, post-procedural bleeding, headache, irritability, myocardial infarction, overstimulation, and respiratory failure. Common adverse reactions were headache, peripheral edema, arthralgia, polyuria, agitation, dizziness, nausea, pharyngitis, abdominal pain, upper abdominal pain, and upper respiratory tract infection.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c475d61d-278a-4fd5-a44c-7bdbd83fea45">
                     <id root="34007201-2d5f-96fd-e063-6394a90a6327"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported during post-approval use of sapropterin dihydrochloride . Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity reactions including anaphylaxis and rash:</content>Most hypersensitivity reactions occurred within several days of initiating treatment
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_165d2049-b757-476c-8ced-b0653cefe9ef">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal reactions: </content>esophagitis, gastritis, oropharyngeal pain, pharyngitis, esophageal pain, abdominal pain, dyspepsia, nausea, and vomiting
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_f57f3981-43e3-462b-92c9-d54de0ce2b19">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hyperactivity:</content>  Two cases have been reported. In one case, the patient received an accidental overdosage of sapropterin dihydrochloride
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_d4553275-042f-4882-9ae7-ae42261c05a6">5.6</linkHtml>), Overdosage (
  
   <linkHtml href="#LINK_62173319-58b3-45df-aec9-5600e001c789">10</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2df07890-a1a0-432e-a6d5-58a9438f8c51">
               <id root="34007201-2d60-96fd-e063-6394a90a6327"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7  DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 4 includes drugs with clinically important drug interactions when administered with sapropterin dihydrochloride and instructions for preventing or managing them.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 4: Clinically Relevant Drug Interactions</content>
                  </paragraph>
                  <table width="510px">
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">Levodopa</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="italics">Clinical Impact</content>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule">Sapropterin dihydrochloride may increase the availability of tyrosine, a precursor of levodopa. Neurologic events were reported postmarketing in patients receiving sapropterin and levodopa concomitantly for a non-PKU indication
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#LINK_78f267d6-30ae-4528-b5e4-dd15f8ba91de">5.5</linkHtml>)]
    
     </content>.
   
    </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="italics">Intervention</content>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule">Monitor patients for a change in neurologic status.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="italics">Clinical Impact</content>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule">In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. This reduction in net BH4 levels may increase Phe levels.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="italics">Intervention</content>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule">Consider monitoring blood Phe levels more frequently during concomitant administration. An increased dosage of sapropterin dihydrochloride may be necessary to achieve a biochemical response.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors such as sildenafil, vardenafil, or tadalafil)</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="italics">Clinical Impact</content>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule">Both sapropterin dihydrochloride and PDE-5 inhibitors may induce vasorelaxation. A reduction in blood pressure could occur; however, the combined use of these medications has not been evaluated in humans.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="italics">Intervention</content>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule">Monitor blood pressure.</td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim)</content>: Can decrease endogenous BH4 levels; monitor blood Phe levels more frequently and adjust sapropterin dihydrochloride dosage as needed.
   
      <linkHtml href="#LINK_2df07890-a1a0-432e-a6d5-58a9438f8c51">(7</linkHtml>)
  
     </paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="underline">Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors)</content>: Potential for vasorelaxation; monitor blood pressure. (
   
      <linkHtml href="#LINK_2df07890-a1a0-432e-a6d5-58a9438f8c51">7</linkHtml>)
  
     </paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_c04ef765-c60e-40b5-99ce-55bd7f6c829d">
               <id root="34007201-2d61-96fd-e063-6394a90a6327"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="LINK_8de46554-059b-4056-8197-fea680bb2f3f">
                     <id root="34007201-2d62-96fd-e063-6394a90a6327"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1  Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from pregnancy safety studies, pharmacovigilance, and published case reports with sapropterin dihydrochloride use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
 
  <content styleCode="italics">(see Data)</content>. Uncontrolled blood phenylalanine concentrations before and during pregnancy are associated with an increased risk of adverse pregnancy outcomes and fetal adverse effects
 
  <content styleCode="italics">(see
  
   <linkHtml href="#CC">Clinical Considerations</linkHtml>)
 
  </content>.

 </paragraph>
                        <paragraph>An embryo-fetal development study with sapropterin dihydrochloride in rats using oral doses up to 3 times the maximum recommended human dose (MRHD) given during the period of organogenesis showed no effects. In a rabbit study using oral administration of sapropterin dihydrochloride during the period of organogenesis, a rare defect, holoprosencephaly, was noted at 10 times the MRHD.</paragraph>
                        <paragraph>All pregnancies have a background risk of major birth defects, pregnancy loss, or other adverse pregnancy outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated background risk of major birth defects and miscarriage in pregnant women with PKU who maintain blood phenylalanine concentrations greater than 600 micromol/L during pregnancy is greater than the corresponding background risk for pregnant women without PKU.</paragraph>
                        <paragraph ID="CC">
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo‑Fetal Risk</content>
                        </paragraph>
                        <paragraph>Uncontrolled blood phenylalanine concentrations before and during pregnancy are associated with an increased risk of adverse pregnancy outcomes and fetal adverse effects. To reduce the risk of hyperphenylalaninemia-induced fetal adverse effects, blood phenylalanine concentrations should be maintained between 120 and 360 micromol/L during pregnancy and during the 3 months before conception
 
  <content styleCode="italics">[see Dosage and Administration
  
   <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Uncontrolled Maternal PKU</content>
                           </content>
                        </paragraph>
                        <paragraph>Available data from the Maternal Phenylketonuria Collaborative Study on 468 pregnancies and 331 live births in PKU‑affected women demonstrated that uncontrolled Phe levels above 600 micromol/L are associated with a very high incidence of neurological, cardiac, facial dysmorphism, and growth anomalies. Control of blood phenylalanine during pregnancy is essential to reduce the incidence of Phe-induced teratogenic effects.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Pregnancy Registry Data</content>
                           </content>
                        </paragraph>
                        <paragraph>Available data from pregnancy sub-registries within the Phenylketonuria Developmental Outcomes and Safety (PKUDOS) Registry and the Sapropterin dihydrochloride Adult Maternal Pediatric European Registry (KAMPER) have identified 72 live births (79 pregnancies) in women with PKU exposed to sapropterin during pregnancy. Three birth defects were reported, including one case each of microcephaly, cleft palate, and tongue tie. The two major birth defects (microcephaly and cleft palate) were associated with Phe levels greater than 360 micromol/L during pregnancy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Animal Data</content>
                        </paragraph>
                        <paragraph>No effects on embryo-fetal development were observed in a reproduction study in rats using oral doses of up to 400 mg/kg per day sapropterin dihydrochloride (about 3 times the MRHD of 20 mg/kg per day, based on body surface area) administered during the period of organogenesis. However, in a rabbit reproduction study, oral administration of a maximum dose of 600 mg/kg per day (about 10 times the MRHD, based on body surface area) during the period of organogenesis was associated with a non-statistically significant increase in the incidence of holoprosencephaly in two high dose-treated litters (4 fetuses), compared to one control-treated litter (1 fetus). </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_705f12f9-5f87-493f-bf66-9c1e5d9bff8a">
                     <id root="34007201-2d63-96fd-e063-6394a90a6327"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2  Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are insufficient data to assess the presence of sapropterin in human milk and no data on the effects on milk production. In postmarketing pregnancy registries, 13 infants were exposed to sapropterin dihydrochloride through breastfeeding. No lactation-related safety concerns were reported in infants of mothers nursing during maternal treatment with sapropterin dihydrochloride . There are no data on the effects on milk production. Sapropterin is present in the milk of lactating rats following intravenous administration, but not following oral administration.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for sapropterin dihydrochloride and any potential adverse effects on the breastfed child from sapropterin dihydrochloride or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4e1cde41-766f-4fd7-98be-b0b8ff457b6b">
                     <id root="3400b7b2-28ec-b3a7-e063-6394a90acd47"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.4  Pediatric Use</title>
                     <text>
                        <paragraph>Pediatric patients with PKU, ages 1 month to 16 years, have been treated with sapropterin dihydrochloride in clinical trials 
  <content styleCode="italics">[see Clinical Studies ( 
   <linkHtml href="#LINK_a78d7a8a-ecb7-4b13-a545-85abb8200bcf">14</linkHtml>)]. 
  </content>
                        </paragraph>
                        <paragraph>The efficacy and safety of sapropterin dihydrochloride have not been established in neonates.  The safety of sapropterin dihydrochloride has been established in children younger than 4 years in trials of 6 months duration and in children 4 years and older in trials of up to 3 years in length 
  <content styleCode="italics">[see Adverse Reactions ( 
   <linkHtml href="#LINK_19984302-67d2-4695-8192-69303591d8c1">6.1</linkHtml>)] 
  </content>.
 </paragraph>
                        <paragraph>In children aged 1 month and older, the efficacy of sapropterin dihydrochloride has been demonstrated in trials of 6 weeks or less in duration 
  <content styleCode="italics">[see Clinical Studies ( 
   <linkHtml href="#LINK_a78d7a8a-ecb7-4b13-a545-85abb8200bcf">14</linkHtml>)] 
  </content>. 
 </paragraph>
                        <paragraph>In a multicenter, open-label, single arm study, 57 patients aged 1 month to 6 years who were defined as sapropterin dihydrochloride responders after 4 weeks of sapropterin dihydrochloride treatment and Phe dietary restriction were treated for 6 months with sapropterin dihydrochloride at 20 mg/kg per day. The effectiveness of sapropterin dihydrochloride alone on reduction of blood Phe levels beyond 4 weeks could not be determined due to concurrent changes in dietary Phe intake during the study. Mean (±SD) blood Phe values over time for patients aged 1 month to &lt;2 years and 2 to &lt;7 years are shown in Figure 1.</paragraph>
                        <table width="95%" ID="Fig1" styleCode="Noautorules">
                           <colgroup>
                              <col align="center" valign="middle" width="100%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold">Figure 1: Mean Blood Phe Level Over Time by Age (years) (N=57)*</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <renderMultiMedia referencedObject="img_3400ba9f-d028-b3f7-e063-6394a90ac53a"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <sup>*</sup>Error bars indicate 95% confidence interval.
    </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <observationMedia ID="img_3400ba9f-d028-b3f7-e063-6394a90ac53a">
                           <text>fig-1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2422a799-ac3f-4f79-813f-9b15480e78ea">
                     <id root="34007201-2d65-96fd-e063-6394a90a6327"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>8.5  Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of sapropterin dihydrochloride in patients with PKU did not include patients aged 65 years and older. It is not known whether these patients respond differently than younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_62173319-58b3-45df-aec9-5600e001c789">
               <id root="34007201-2d66-96fd-e063-6394a90a6327"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10  OVERDOSAGE</title>
               <text>
                  <paragraph>Two unintentional overdosages with sapropterin dihydrochloride have been reported. One adult patient in a sapropterin dihydrochloride clinical trial received a single sapropterin dihydrochloride dose of 4,500 mg (36 mg/kg) instead of 2,600 mg (20 mg/kg). The patient reported mild headache and mild dizziness immediately after taking the dose; both symptoms resolved within 1 hour with no treatment intervention. There were no associated laboratory test abnormalities. The patient suspended therapy for 24 hours and then restarted sapropterin dihydrochloride with no reports of abnormal signs or symptoms. In postmarketing, one pediatric patient received sapropterin dihydrochloride doses of 45 mg/kg per day instead of 20 mg/kg per day. The patient reported hyperactivity that began at an unspecified time after overdosage and resolved after the sapropterin dihydrochloride dose was reduced to 20 mg/kg per day. </paragraph>
                  <paragraph>In a clinical study to evaluate the effects of sapropterin dihydrochloride on cardiac repolarization, a single supra-therapeutic dose of 100 mg/kg (5 times the maximum recommended dose) was administered to 54 healthy adults. No serious adverse reactions were reported during the study. The only adverse reactions reported in more than 1 subject who received the supra-therapeutic dose were upper abdominal pain (6%) and dizziness (4%). A dose-dependent shortening of the QT interval was observed
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#LINK_3a6ad8df-979f-404e-a6e8-5c0299c64136">12.2</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>Patients should be advised to notify their physicians in cases of overdosage.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
            </section>
         </component>
         <component>
            <section ID="LINK_ee639fee-ca35-4c15-b47a-0d15c8cee059">
               <id root="3400c22a-a77a-b46c-e063-6394a90ac35b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph>Zelvysia (sapropterin dihydrochloride) is an orally administered Phenylalanine Hydroxylase activator (or PAH activator). Sapropterin dihydrochloride, the active pharmaceutical ingredient in Zelvysia , is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Sapropterin dihydrochloride is an off-white to pale yellow powder.</paragraph>
                  <paragraph>The chemical name of sapropterin dihydrochloride is (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(1H)-pteridinone dihydrochloride and the molecular formula is C 
  <sub>9</sub>H 
  <sub>15</sub>N 
  <sub>5</sub>O 
  <sub>3</sub>·2HCl with a molecular weight of 314.17.
 </paragraph>
                  <paragraph>Sapropterin dihydrochloride has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3400c1b9-5a51-a9e5-e063-6294a90a5d86"/>
                  </paragraph>
                  <paragraph>Zelvysia is supplied as powder for oral solution containing 100 mg of sapropterin dihydrochloride (equivalent to 76.8 mg of sapropterin base). Zelvysia is also supplied as powder for oral solution containing 500 mg of sapropterin dihydrochloride (equivalent to 384 mg of sapropterin base). </paragraph>
                  <paragraph>Zelvysia powder for oral solution is off-white to yellow in color. Each unit dose packet contains the following inactive ingredients: ascorbic acid, mannitol (USP) and potassium citrate (USP).</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="img_3400c1b9-5a51-a9e5-e063-6294a90a5d86">
                     <text>descrip</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="description.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_54915c86-4487-4a8f-8e7c-39c5f8a56b99">
               <id root="34007201-2d68-96fd-e063-6394a90a6327"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="LINK_7a70710b-af89-490c-a181-71e8d648507b">
                     <id root="34007201-2d69-96fd-e063-6394a90a6327"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Sapropterin dihydrochloride is a synthetic form of BH4, the cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates Phe through an oxidative reaction to form tyrosine. In patients with PKU, PAH activity is absent or deficient. Treatment with BH4 can activate residual PAH enzyme activity, improve the normal oxidative metabolism of Phe, and decrease Phe levels in some patients.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3a6ad8df-979f-404e-a6e8-5c0299c64136">
                     <id root="34007201-2d6a-96fd-e063-6394a90a6327"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>In PKU patients who are responsive to BH4 treatment, blood Phe levels decrease within 24 hours after a single administration of sapropterin dihydrochloride, although maximal effect on Phe level may take up to a month, depending on the patient. A single daily dose of sapropterin dihydrochloride is adequate to maintain stable blood Phe levels over a 24-hour period. Twelve patients with blood Phe levels ranging from 516 to 986 μmol/L (mean 747 ± 153 μmol/L) were assessed with 24‑hour blood Phe level monitoring following a daily morning dose of 10 mg/kg per day. The blood Phe level remained stable during a 24‑hour observation period. No substantial increases in blood Phe levels were observed following food intake throughout the 24-hour period.</paragraph>
                        <paragraph>Sapropterin dihydrochloride  dose-response relationship was studied in an open-label, forced titration study at doses of 5 mg/kg per day, then 20 mg/kg per day, and then 10 mg/kg per day (Study 3)
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#LINK_0f61934e-e2bb-4d47-bfb5-5a93d8f6fa3b">14</linkHtml>)]
 
  </content>. Individual blood Phe levels were highly variable among patients. The mean blood Phe level observed at the end of each 2-week dosing period decreased as the dose of sapropterin dihydrochloride increased, demonstrating an inverse relationship between the dose of sapropterin dihydrochloride and mean blood Phe levels. 

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>A thorough QTc study was performed in 56 healthy adults.  This randomized, placebo and active controlled crossover study was conducted to determine if a single supra-therapeutic (100 mg/kg) dose of sapropterin dihydrochloride  or a single therapeutic dose (20 mg/kg) of sapropterin dihydrochloride  had an effect on cardiac repolarization. In this study, sapropterin dihydrochloride was administered after dissolving tablets in water under fed condition. This study demonstrated a dose-dependent shortening of the QT interval. The maximum placebo-subtracted mean change from baseline of the QTc interval was -3.69 and -8.32 ms (lower bound of 90% CI: -5.3 and -10.6 ms) at 20 and 100 mg/kg, respectively.   </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_022144f9-e6a6-4de9-87c6-65867107caa6">
                     <id root="34007201-2d6b-96fd-e063-6394a90a6327"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Studies in healthy subjects have shown comparable absorption of sapropterin when tablets are dissolved in water or orange juice and taken under fasted conditions. Administration of dissolved tablets after a high-fat/high-calorie meal resulted in mean increases in C
 
  <sub>max</sub>of 84% and AUC of 87% (dissolved in water). However, there was extensive variability in individual subject values for C
 
  <sub>max</sub>and AUC across the different modes of administration and meal conditions. In the clinical trials of sapropterin dihydrochloride  , drug was administered in the morning as a dissolved tablet without regard to meals. The mean elimination half-life in PKU patients was approximately 6.7 hours (range 3.9 to 17 hours), comparable with values seen in healthy subjects (range 3.0 to 5.3 hours). 

 </paragraph>
                        <paragraph>A study in healthy adults with 10 mg/kg of sapropterin dihydrochloride demonstrated that the absorption via intact tablet administration was 40% greater than via dissolved tablet administration under fasted conditions based on AUC
 
  <sub>0-t</sub>. The administration of intact tablets under fed conditions resulted in an approximately 43% increase in the extent of absorption compared to fasted conditions based on AUC
 
  <sub>0-t</sub>
                           <content styleCode="italics">[see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Population pharmacokinetic analysis of sapropterin including patients from 1 month to 49 years of age showed that body weight is the only covariate substantially affecting clearance or distribution volume (see Table 5). Pharmacokinetics in patients &gt;49 years of age have not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 5: Apparent Plasma Clearance by Age</content>
                        </paragraph>
                        <table>
                           <col width="105.55pt"/>
                           <col width="68.35pt"/>
                           <col width="75.3pt"/>
                           <col width="75.3pt"/>
                           <col width="73.6pt"/>
                           <col width="69.9pt"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Parameter</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                                    <paragraph>0 to &lt;1 yr
     
      <sup>*</sup>
                                    </paragraph>
                                    <paragraph>(N=10)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                                    <paragraph>1 to &lt;6 yr
     
      <sup>*</sup>
                                    </paragraph>
                                    <paragraph>(N=57)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                                    <paragraph>6 to &lt;12 yr
     
      <sup>†</sup>
                                    </paragraph>
                                    <paragraph>(N=23)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                                    <paragraph>12 to &lt;18 yr
     
      <sup>†</sup>
                                    </paragraph>
                                    <paragraph>(N=24)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                                    <paragraph>≥18 yr
     
      <sup>†</sup>
                                    </paragraph>
                                    <paragraph>(N=42)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">CL/F (L/hr/kg)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Mean ± SD</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(Median)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule" valign="top">
                                    <paragraph>81.5 ± 92.4 
      <br/>  (53.6)
     </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule" valign="top">
                                    <paragraph>50.7 ± 20.1 
      <br/>  (48.4)
     </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule" valign="top">
                                    <paragraph>51.7 ± 21.9 
      <br/>  (47.4)
     </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule" valign="top">
                                    <paragraph>39.2 ± 9.3 
      <br/>  (38.3)
     </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule Lrule Rrule" valign="top">
                                    <paragraph>37.9 ± 20.2 
      <br/>  (31.8)
     </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>*</sup>Evaluated at 20 mg/kg per day dose.

 </paragraph>
                        <paragraph>
                           <sup>†</sup>Evaluated at 5, 10, or 20 mg/kg per day doses.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Sapropterin is a synthetic form of tetrahydrobiopterin (BH4) and is expected to be metabolized and recycled by the same endogenous enzymes. In vivo endogenous BH4 is converted to quinoid dihydrobiopterin and is metabolized to dihydrobiopterin and biopterin. The enzymes dihydrofolate reductase and dihydropteridine reductase are responsible for the metabolism and recycling of BH4.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug</content>
                           <content styleCode="underline">Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies</content>
                        </paragraph>
                        <paragraph>In healthy subjects, administration of a single dose of sapropterin dihydrochloride  at the maximum therapeutic dose of 20 mg/kg had no effect on the pharmacokinetics of a single dose of digoxin (P-gp substrate) administered concomitantly.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically</content>
                        </paragraph>
                        <paragraph>The potential for sapropterin to induce or inhibit cytochrome P450 enzymes was evaluated in in vitro studies which showed sapropterin did not inhibit CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5, nor induce CYP 1A2, 2B6, or 3A4/5.</paragraph>
                        <paragraph>In vitro sapropterin did not inhibit OAT1, OAT3, OCT2, MATE1, and MATE2-K transporters. The potential for sapropterin to inhibit OATP1B1 and OATP1B3 has not been adequately studied. In vitro, sapropterin inhibits breast cancer resistance protein (BCRP) but the potential for a clinically significant increase in systemic exposure of BCRP substrates by sapropterin dihydrochloride appears to be low.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1a9384c2-92c7-4577-8e01-6a89a075bda1">
               <id root="34007201-2d6c-96fd-e063-6394a90a6327"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20240831"/>
               <component>
                  <section ID="LINK_848ede41-d03d-4e0d-9df7-5a1d8a675d41">
                     <id root="34007201-2d6d-96fd-e063-6394a90a6327"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>A 2-year carcinogenicity study was conducted in F-344 rats, and a 78-week carcinogenicity study was conducted in CD-1 mice. In the 104-week oral carcinogenicity study in rats, sapropterin dihydrochloride doses of 25, 80, and 250 mg/kg per day (0.2, 0.7, and 2 times the maximum recommended human dose of 20 mg/kg per day, respectively, based on body surface area) were used. In the 78-week oral carcinogenicity study in mice, sapropterin dihydrochloride doses of 25, 80, and 250 mg/kg per day (0.1, 0.3, and 2 times the recommended human dose, respectively, based on body surface area) were used. In the 2‑year rat carcinogenicity study, there was a statistically significant increase in the incidence of benign adrenal pheochromocytoma in male rats treated with the 250 mg/kg per day (about 2 times the maximum recommended human dose, based on body surface area) dose, as compared to vehicle treated rats. The mouse carcinogenicity study showed no evidence of a carcinogenic effect, but the study was not ideal due to its duration of 78 instead of 104 weeks.</paragraph>
                        <paragraph>Sapropterin dihydrochloride was genotoxic in the
 
  <content styleCode="italics">in vitro</content>Ames test at concentrations of 625 µg (TA98) and 5000 µg (TA100) per plate, without metabolic activation. However, no genotoxicity was observed in the
 
  <content styleCode="italics">in vitro</content>Ames test with metabolic activation. Sapropterin dihydrochloride was genotoxic in the
 
  <content styleCode="italics">in vitro</content>chromosomal aberration assay in Chinese hamster lung cells at concentrations of 0.25 and 0.5 mM. Sapropterin dihydrochloride was not mutagenic in the
 
  <content styleCode="italics">in vivo</content>micronucleus assay in mice at doses up to 2000 mg/kg per day (about 8 times the maximum recommended human dose of 20 mg/kg per day, based on body surface area). Sapropterin dihydrochloride, at oral doses up to 400 mg/kg per day (about 3 times the maximum recommended human dose, based on body surface area) was found to have no effect on fertility and reproductive function of male and female rats.

 </paragraph>
                     </text>
                     <effectiveTime value="20240831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a78d7a8a-ecb7-4b13-a545-85abb8200bcf">
               <id root="3400c062-63b9-b4d2-e063-6394a90a44af"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of sapropterin dihydrochloride  was evaluated in five clinical studies in patients with PKU.</paragraph>
                  <paragraph>Study 1 was a multicenter, open-label, uncontrolled clinical trial of 489 patients with PKU, ages 8 to 48 years (mean 22 years), who had baseline blood Phe levels ≥ 450 μmol/L and who were not on Phe-restricted diets. All patients received treatment with sapropterin dihydrochloride  10 mg/kg per day for 8 days. For the purposes of this study, response to sapropterin dihydrochloride  treatment was defined as a ≥ 30% decrease in blood Phe from baseline. At Day 8, 96 patients (20%) were identified as responders.</paragraph>
                  <paragraph>Study 2 was a multicenter, double-blind, placebo-controlled study of 88 patients with PKU who responded to sapropterin dihydrochloride  in Study 1. After a washout period from Study 1, patients were randomized equally to either sapropterin dihydrochloride  10 mg/kg per day (N=41) or placebo (N=47) for 6 weeks. Efficacy was assessed by the mean change in blood Phe level from baseline to Week 6 in the sapropterin dihydrochloride  -treated group as compared to the mean change in the placebo group.</paragraph>
                  <paragraph>The results showed that at baseline, the mean (±SD) blood Phe level was 843 (±300) μmol/L in the sapropterin dihydrochloride-treated group and 888 (±323) μmol/L in the placebo group. At Week 6, the sapropterin dihydrochloride  treated group had a mean (±SD) blood Phe level of 607 (±377) μmol/L, and the placebo group had a mean blood Phe level of 891 (±348) μmol/L. At Week 6, the sapropterin dihydrochloride- and placebo treated groups had mean changes in blood Phe level of –239 and 6 μmol/L, respectively (mean percent changes of –29% (±32) and 3% (±33), respectively). The difference between the groups was statistically significant (p &lt; 0.001) (Table 6).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 6: Blood Phe Results in Study 2</content>
                  </paragraph>
                  <table>
                     <colgroup>
                        <col width="2.5in"/>
                        <col/>
                        <col width="1.75in"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Sapropterin (N=41)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Placebo (N=47)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Baseline Blood Phe Level</content>*  
      <content styleCode="bold">(μ</content>
                                 <content styleCode="bold">mol/L)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Mean (±SD)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>843 (±300)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>888 (±323)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Percentiles (25 
      <sup>th</sup>, 75 
      <sup>th</sup>)
     </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>620, 990</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>618, 1141</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Week 6 Blood Phe Level (μ</content>
                                 <content styleCode="bold">mol/L)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Mean (±SD)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>607 (±377)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>891 (±348)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Percentiles (25 
      <sup>th</sup>, 75 
      <sup>th</sup>)
     </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>307, 812</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>619, 1143</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Mean Change in Blood Phe From Baseline to Week 6 (μ</content>
                                 <content styleCode="bold">mol/L)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Adjusted Mean (±SE)†</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>-239 (±38)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>6 (±36)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Percentiles (25 
      <sup>th</sup>, 75 
      <sup>th</sup>)
     </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>-397, -92</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>-96, 93</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Mean Percent Change in Blood Phe From Baseline to Week 6</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Mean (±SD)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>- 29 (±32)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>3 (±33)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>Percentiles (25 
      <sup>th</sup>, 75 
      <sup>th</sup>)
     </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>-61, -11</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Toprule Lrule Rrule">
                              <paragraph>-13, 12</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>*</sup>The mean baseline levels shown in this table represent the mean of 3 pretreatment levels (Wk -2, Wk -1, and Wk 0). Treatment with sapropterin dihydrochloride or placebo started at Wk 0.
 </paragraph>
                  <paragraph>
                     <sup>†</sup>p-value &lt; 0.001, adjusted mean and standard error from an ANCOVA model with change in blood Phe level from baseline to Week 6 as the response variable, and both treatment group and baseline blood Phe level as covariates.
 </paragraph>
                  <paragraph>Change in blood Phe was noted in the sapropterin dihydrochloride -treated group at Week 1 and was sustained through Week 6 (Figure 2).</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3400b7b2-28ef-b3a7-e063-6394a90acd47"/>
                  </paragraph>
                  <paragraph>Study 3 was a multicenter, open-label, extension study in which 80 patients who responded to sapropterin dihydrochloride  treatment in Study 1 and completed Study 2 underwent 6 weeks of forced dose-titration with 3 different doses of sapropterin dihydrochloride. Treatments consisted of 3 consecutive 2-week courses of sapropterin dihydrochloride at doses of 5, then 20, and then 10 mg/kg per day. Blood Phe level was monitored after 2 weeks of treatment at each dose level. At baseline, mean (±SD) blood Phe was 844 (±398) μmol/L. At the end of treatment with 5, 10, and 20 mg/kg per day, mean (±SD) blood Phe levels were 744 (±384) μmol/L, 640 (±382) μmol/L, and 581 (±399) μmol/L, respectively (Table 7).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 7: Blood Phe Results From Forced Dose-Titration in Study 3</content>
                  </paragraph>
                  <table>
                     <colgroup>
                        <col width="98.55pt"/>
                        <col width="53.9pt"/>
                        <col width="106.65pt"/>
                        <col width="159.4pt"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Sapropterin Dihydrochloride Dose Level (mg/kg per day)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">No. of Patients</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Mean (</content>± 
      <content styleCode="bold">SD) Blood Phe Level (μ</content>
                                 <content styleCode="bold">mol/L)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Mean Changes (</content>± 
      <content styleCode="bold">SD) in Blood Phe Level From Week 0 (μ</content>
                                 <content styleCode="bold">mol/L)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Baseline</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(No Treatment)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>80</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>844 (±398)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>—</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">5</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>80</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>744 (±384)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>‑100 (±295)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">10</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>80</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>640 (±382)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>‑204 (±303)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">20</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>80</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>581 (±399)</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>-263 (±318)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Study 4 was a multicenter study of 90 pediatric patients with PKU, ages 4 to 12 years, who were on Phe‑restricted diets and who had blood Phe levels ≤480 μmol/L at screening. All patients were treated with open-label sapropterin dihydrochloride 20 mg/kg per day for 8 days. Response to sapropterin dihydrochloride  was defined as a ≥30% decrease in blood Phe from baseline at Day 8. At Day 8, 50 patients (56%) had a ≥30% decrease in blood Phe.</paragraph>
                  <paragraph>Study 5 was an open label, single arm, multicenter trial in 93 pediatric patients with PKU, aged 1 month to 6 years, who had Phe levels greater than or equal to 360 μmol/L at screening.   All patients were treated with sapropterin dihydrochloride at 20 mg/kg per day and maintained on a Phe-restricted diet.   At Week 4, 57 patients (61%) were identified as responders (defined as ≥ 30% decreased in blood Phe from baseline) 
  <content styleCode="italics">[see 
   <linkHtml href="#Fig1">Use in Specific Populations (8.4) Figure 1</linkHtml>] 
  </content>.
 </paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="img_3400b7b2-28ef-b3a7-e063-6394a90acd47">
                     <text>fig-2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_20806723-cec9-4929-a41d-df773052433e">
               <id root="34007201-2d6f-96fd-e063-6394a90a6327"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Zelvysia for Oral Solution</content>
                  </paragraph>
                  <paragraph>Supplied as an off-white to yellow powder supplied in unit dose packets as follows:</paragraph>
                  <paragraph>100 mg sapropterin dihydrochloride per packet:</paragraph>
                  <paragraph>NDC 73289-0070-2    Carton of 30 unit dose packets</paragraph>
                  <paragraph>NDC 73289-0070-1     Single unit dose packet</paragraph>
                  <paragraph>500 mg sapropterin dihydrochloride per packet:</paragraph>
                  <paragraph>NDC 73289-0071-2     Carton of 30 unit dose packets</paragraph>
                  <paragraph>NDC 73289-0071-1     Single unit dose packet</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Store Zelvysia for oral solution at 20ºC to 25ºC (68ºF to 77ºF); excursions allowed between 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Protect from moisture.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3206b2c0-a5f8-43ba-9400-c822979f4745">
               <id root="34007201-2d70-96fd-e063-6394a90a6327"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions Including Anaphylaxis</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers to discontinue Zelvysia and contact the patient’s healthcare provider immediately if they experience symptoms of anaphylaxis, including (but not limited to) wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. Continue nutritional management including dietary protein and Phe restriction
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_165d2049-b757-476c-8ced-b0653cefe9ef">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Upper Gastrointestinal Mucosal Inflammation</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers to contact their healthcare provider if the patient experiences signs and symptoms suggestive of upper GI mucosal inflammation, including nausea, vomiting, dysphagia, dyspepsia, loss of appetite; oropharyngeal, esophageal, or upper abdominal pain
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypophenylalaninemia</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers that Zelvysia may cause hypophenylalaninemia (low blood Phe levels), especially in pediatric patients younger than 7 years of age
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_233e7852-f1ed-4e5d-973c-c12c60adb355">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Monitoring of Blood Phe Levels</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers that frequent blood Phe monitoring is important to ensure blood Phe levels are in the desirable range and that they should maintain dietary protein and Phe restriction while on Zelvysia
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_cbb9c000-cfae-4314-8428-28033fc2c327">5.4</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>Prolonged hyperphenylalaninemia (high blood Phe levels) in patients with PKU can result in severe neurologic damage, including intellectual disability, developmental delay, microcephaly, delayed speech,seizures, and behavioral abnormalities
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_cbb9c000-cfae-4314-8428-28033fc2c327">5.4</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lack of Biochemical Response to Zelvysia</content>
                  </paragraph>
                  <paragraph>Some patients do not show a biochemical response (blood Phe reduction) when treated with Zelvysia . Advise patients and caregivers to discontinue treatment with Zelvysia if the patient does not show an adequate biochemical response in blood Phe after one month of treatment with Zelvysia  20 mg/kg per day
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#LINK_cbb9c000-cfae-4314-8428-28033fc2c327">5.5</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Interaction with Levodopa</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers that patients with underlying neurological disorders taking Zelvysia in combination with levodopa may experience seizures, exacerbation of seizures, over-stimulation or irritability. Inform patients and caregivers to contact their healthcare provider if the patient has a change in neurologic status during treatment with Zelvysia
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_78f267d6-30ae-4528-b5e4-dd15f8ba91de">5.6</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hyperactivity</content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers that Zelvysia may cause hyperactivity and to contact their healthcare provider if the patient experiences hyperactivity, restlessness, fidgeting, or excessive talking
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_d4553275-042f-4882-9ae7-ae42261c05a6">5.7</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosing and Monitoring</content>
                     <content styleCode="italics">
                        <content styleCode="italics">[see Dosage and Administration (
   
    <linkHtml href="#LINK_afba740c-6d56-4676-9532-052b8316c37f">2.2</linkHtml>)]
  
   </content>
                     </content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers of the following:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <paragraph>Zelvysia should be used in conjunction with a PKU-specific diet, including dietary protein and Phe restriction.</paragraph>
                     </item>
                     <item>
                        <paragraph>Dietary protein and Phe intake should not be modified during the Zelvysia evaluation period when assessing biochemical response.</paragraph>
                     </item>
                     <item>
                        <paragraph>The patient must be evaluated for changes in blood Phe after being treated with Zelvysia at the recommended dose(s) for age to determine if they have a biochemical response and that blood Phe levels and dietary Phe intake should be assessed frequently during the first month of Zelvysia treatment.</paragraph>
                     </item>
                     <item>
                        <paragraph>Monitoring of blood Phe levels is important during Zelvysia treatment.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Preparation and Administration</content>
                     <content styleCode="italics">[see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]
 
  </content>
                  </paragraph>
                  <paragraph>Advise patients and caregivers:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <paragraph>Zelvysia powder for oral solution should be dissolved in water or apple juice or stirred in a small amount of soft food such as apple sauce or pudding.</paragraph>
                     </item>
                     <item>
                        <paragraph>Take Zelvysia with a meal, preferably at the same time each day.</paragraph>
                     </item>
                  </list>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Aucta Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Piscataway, NJ 08854</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="LINK_04ea52f1-9cc9-448e-ab18-8ed71b4ff672">
               <id root="34007201-2d71-96fd-e063-6394a90a6327"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <table width="596.8px">
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <paragraph>
                                 <content styleCode="bold">ZELVYSIA (zel-VIS-ee-ah)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(sapropterin dihydrochloride)</content>
                              </paragraph>
                              <content styleCode="bold">powder for oral solution</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">What is ZELVYSIA?</content>
                              <br/>  Zelvysia is a prescription medicine used to lower blood levels of phenylalanine (Phe), in adults and children one month of age and older with a certain type of Phenylketonuria (PKU). Zelvysia is used along with a Phe-restricted diet.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">What should I tell my doctor before taking Zelvysia?</content>
                              <paragraph>
                                 <content styleCode="bold">Before you take Zelvysia , tell your doctor about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are allergic to sapropterin dihydrochloride or any of the ingredients in Zelvysia . See the list of ingredients in Zelvysia at the end of this leaflet.</item>
                                 <item>have poor nutrition or have loss of appetite.</item>
                                 <item>are pregnant or plan to become pregnant.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if Zelvysia  passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take Zelvysia .</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your doctor about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, herbal, and dietary supplements. Zelvysia  and other medicines may interact with each other.
    
     </paragraph>
                              <paragraph>Especially tell your doctor if you take:</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>a medicine that contains levodopa</item>
                                 <item>an antifolate medicine</item>
                                 <item>sildenafil (Revatio, Viagra), tadalafil (Adcirca, Cialis), vardenafil (Staxyn, Levitra)</item>
                              </list>
                              <paragraph>Tell your doctor if you are not sure if your medicine is one that is listed above.</paragraph>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. 
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">How should I take ZELVYSIA ?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take Zelvysia exactly as your doctor tells you. Your doctor should tell you how much Zelvysia to take and when to take it.</item>
                                 <item>Your doctor may change your dose of Zelvysia depending on how you respond to treatment.</item>
                                 <item>Take Zelvysia 1 time each day with a meal. It is best to take Zelvysia at the same time each day.</item>
                                 <item>Sapropterin dihydrochloride comes as a powder for oral solution.
      
       <list listType="unordered" styleCode="Circle">
                                       <item>Be sure that you know what dose of Zelvysia powder your doctor prescribed and whether you should use sapropterin dihydrochloride 100 mg packets, sapropterin dihydrochloride 500 mg packets, or both types of packets to prepare your dose.</item>
                                       <item>Open Zelvysia powder packets only when you are ready to use them.</item>
                                       <item>
                                          <content styleCode="bold">Zelvysia powder for oral solution should be dissolved in water or apple juice.</content>You may also mix the powder for oral solution in a small amount of soft food, such as apple sauce or pudding before taking.
       
        </item>
                                       <item>See the detailed “Instructions for Use” that comes with Zelvysia for information about the correct way to dissolve and take a dose of Zelvysia powder for oral solution.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>It is not possible to know if Zelvysia will work for you until you start taking Zelvysia . Your doctor will check your blood Phe levels when you start taking Zelvysia to see if the medicine is working.</item>
                              </list>
                              <list listType="unordered">
                                 <item>During treatment with Zelvysia :
      
       <list listType="unordered" styleCode="Circle">
                                       <item>Any change you make to your diet may affect your blood Phe level. Follow your doctor’s instructions carefully and do not make any changes to your dietary Phe intake without first talking with your doctor. Even if you take Zelvysia, if your Phe blood levels are not well controlled, you can develop severe neurologic problems.</item>
                                       <item>Your doctor should continue to monitor your blood Phe levels often during your treatment with Zelvysia  
        
         <content styleCode="bold">to make sure that your blood Phe levels are not too high or too low</content>.
       
        </item>
                                       <item>If you have a fever, or if you are sick, your blood Phe level may go up. Tell your doctor as soon as possible so they can change your dose of Zelvysia to help keep your blood Phe levels in the desired range.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered">
                                 <item>If you forget to take your dose of Zelvysia, take it as soon as you remember that day. Do not take 2 doses in a day.</item>
                                 <item>If you take too much Zelvysia, call your doctor for advice.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">What are the possible side effects of ZELVYSIA ?</content>
                              <paragraph>
                                 <content styleCode="bold">Zelvysia can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Severe allergic reactions.</content>Stop taking Zelvysia and get medical help right away if you develop any of these symptoms of a severe allergic reaction:
     
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <list listType="unordered">
                                 <item>wheezing or trouble breathing</item>
                                 <item>coughing</item>
                                 <item>feeling lightheaded or you faint</item>
                              </list>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <list listType="unordered">
                                 <item>flushing</item>
                                 <item>nausea</item>
                                 <item>rash</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Inflammation of the lining of the stomach
       
        <content styleCode="bold">(gastritis) or esophagus (esophagitis)</content>.
      
       </content>Gastritis or esophagitis can happen with Zelvysia and may be severe.
      
       <content styleCode="bold">Call your doctor right away if you have any of these signs or symptoms:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>severe upper stomach-area (abdominal) discomfort or pain, nausea and vomiting</item>
                                       <item>blood in your vomit or stool</item>
                                       <item>black, tarry stools</item>
                                       <item>difficulty swallowing</item>
                                       <item>loss of appetite</item>
                                       <item>pain in the throat</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Phe levels that are too low.</content>Some children under the age of 7 years who take high doses of Zelvysia each day may experience low Phe levels.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Too much or constant activity (hyperactivity) can happen with Zelvysia</content>. Tell your doctor if you have any signs of hyperactivity, including:
      
       <list listType="unordered" styleCode="Circle">
                                       <item>fidgeting or moving around too much</item>
                                       <item>talking too much 
         <br/>
                                       </item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>The most common side effects of Zelvysia are:</paragraph>
                              <list listType="unordered">
                                 <item>headache</item>
                                 <item>runny nose and nasal congestion</item>
                                 <item>sore throat</item>
                                 <item>diarrhea</item>
                                 <item>vomiting</item>
                                 <item>cough 
       <br/>
                                 </item>
                              </list>
                              <paragraph>Tell your doctor if you have any side effect that bothers you or that does not go away.</paragraph>
                              <paragraph>These are not all the possible side effects of Zelvysia . For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">How should I store ZELVYSIA ?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store Zelvysia at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Protect from moisture. 
       <br/>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep Zelvysia and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">General information about the safe and effective use of ZELVYSIA .</content>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Zelvysia n for a condition for which it was not prescribed. Do not give Zelvysia to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or doctor for information about Zelvysia that is written for health professionals.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">What are the ingredients in ZELVYSIA ?</content>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content>sapropterin dihydrochloride.
    
     </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Zelvysia powder for oral solution inactive ingredients:</content>ascorbic acid, mannitol, and potassium citrate.
    
     </paragraph>
                              <paragraph>Manufactured for: </paragraph>
                              <paragraph>Aucta Pharmaceuticals, Inc. </paragraph>
                              <paragraph>Piscataway, NJ 08854</paragraph>
                              <paragraph>For more information, go to www.Zelvysia.com or call 1-800-655-9902.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration                                                                                       </paragraph>
                  <paragraph>Revised: 01/2025 
  <br/>  LB5405-01
 </paragraph>
               </text>
               <effectiveTime value="20250429"/>
            </section>
         </component>
         <component>
            <section ID="LINK_47815120-9631-4155-b3ce-953d07e45134">
               <id root="3401eacf-06d8-31b2-e063-6394a90a96fc"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>INSTRUCTIONS FOR USE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Zelvysia (zel-VIS-ee-ah)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(sapropterin dihydrochloride)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">powder for oral solution</content>
                  </paragraph>
                  <paragraph>Read this Instructions for Use before you start taking Zelvysia and each time you refill your prescription. There may be new information. This information does not take the place of talking with your healthcare provider about your treatment. Talk to your doctor if you have any questions about the right dose of Zelvysia to take or how to mix it.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Zelvysia comes as a packet containing powder.</item>
                     <item>Take Zelvysia exactly as your doctor tells you. Your doctor should tell you how much Zelvysia to take and when to take it.</item>
                     <item>Your doctor may change your dose of Zelvysia depending on how you respond to treatment, or based on your baby’s weight.</item>
                     <item>If your baby weighs 22 pounds or less, follow the section called “ 
   <content styleCode="bold">Instructions for giving Zelvysia powder for oral solution (Zelvysia 100 mg packets) to babies who weigh 22 pounds or less</content>”.
  </item>
                     <item>Take Zelvysia 1 time each day with a meal. It is best to take Zelvysia at the same time each day.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Instructions for taking Zelvysia powder for oral solution:</content>
                  </paragraph>
                  <paragraph>For babies who weigh 22 pounds or less, see the section below called “ 
  <content styleCode="bold">Instructions for giving Zelvysia powder for oral solution (Zelvysia 100 mg packets) to babies who weigh 22 pounds or less.”</content>
                  </paragraph>
                  <paragraph>Zelvysia powder for oral solution should be dissolved in water or apple juice. The powder for oral solution may also be mixed in a small amount of soft foods, such as apple sauce or pudding.</paragraph>
                  <paragraph>
                     <content styleCode="bold">To dissolve Zelvysia powder for oral solution:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <paragraph>Be sure that you know what dose of Zelvysia your doctor has prescribed and whether you should use Zelvysia 100 mg packets, Zelvysia 500 mg packets, or both types of packets to prepare your dose.</paragraph>
                     </item>
                     <item>
                        <paragraph>Open the packet(s) of Zelvysia powder for oral solution by folding and tearing, or cutting at the dotted line in the upper right corner of the packet. Open the packet(s) only when you are ready to use them.</paragraph>
                     </item>
                     <item>
                        <paragraph>Empty the contents of the packet(s) into 4 ounces to 8 ounces (1/2 cup to 1 cup) of water or apple juice.</paragraph>
                     </item>
                     <item>Drink within 30 minutes.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Instructions for giving Zelvysia powder for oral solution (Zelvysia 100 mg packets) to babies who weigh 22 pounds or less:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>The dose of Zelvysia is based on body weight. This will change as your baby grows. Your doctor will tell you:
	
   <list listType="unordered" styleCode="Circle">
                           <item>the number of Zelvysia 100 mg packets needed for one dose</item>
                           <item>the amount of water or apple juice needed to mix one dose of Zelvysia</item>
                           <item>the amount of the mixture (powder and water or apple juice) you will need to give your baby his or her prescribed dose of medicine.</item>
                        </list>
                     </item>
                     <item>Give your baby the prescribed amount of mixture (powder and water or apple juice) within 30 minutes after mixing. If you are not able to give your baby’s dose within 30 minutes after mixing, pour the unused medicine into the trash. You will need to mix a new dose.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Supplies needed to mix and give your baby’s dose of Zelvysia powder for oral solution:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>the number of Zelvysia 100 mg packets needed for one dose</item>
                     <item>a small cup of water or apple juice</item>
                     <item>one 30 mL medicine cup for mixing</item>
                     <item>small spoon or clean utensil for mixing</item>
                     <item>10 mL oral dosing syringe</item>
                     <item>scissors (optional)</item>
                  </list>
                  <paragraph>Ask your pharmacist for a 30 mL medicine cup for mixing and an oral dosing syringe if you do not have these supplies.</paragraph>
                  <table width="694px">
                     <colgroup>
                        <col/>
                        <col/>
                        <col/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 1:</content>
                           </td>
                           <td>Find a clean, flat work surface.</td>
                           <td/>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 2: </content>
                           </td>
                           <td>Place a small cup of water or apple juice, the oral dosing syringe, and an empty medicine cup on your clean, flat work surface (see Figure A).</td>
                           <td>
                              <renderMultiMedia referencedObject="img_34008ab2-335a-8f63-e063-6294a90a40d9"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">
                                 <content styleCode="bold">Step 3:</content>
                              </content>
                           </td>
                           <td>Pour 5 mL or 10 mL of water or apple juice from the small cup into the medicine cup, as instructed by your doctor. Check to make sure that the amount of liquid lines up with the amount that your doctor tells you (see Figure B).</td>
                           <td>
                              <renderMultiMedia referencedObject="img_34008ab2-335c-8f63-e063-6294a90a40d9"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 4:</content>
                           </td>
                           <td>Check the label on the Zelvysia packet(s). If the packet is marked Zelvysia 100 mg, empty the entire contents of the Zelvysia packet into the medicine cup (see Figure C).</td>
                           <td>
                              <renderMultiMedia referencedObject="img_3400a86f-2d9f-a1da-e063-6294a90a03bd"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 5:</content>
                              <content styleCode="bold"/>
                           </td>
                           <td>Stir the mixture with the small spoon or other clean utensil until all of the powder completely dissolves (see Figure D).</td>
                           <td>
                              <renderMultiMedia referencedObject="img_3400af6f-1c5c-ace4-e063-6394a90aa473"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 6:</content>
                           </td>
                           <td>To give a dose of Zelvysia to your baby: Place the tip of the oral dosing syringe into the liquid inside the medicine cup. Pull back on the plunger and draw up the amount of the mixture prescribed by your doctor (see Figure E).</td>
                           <td>
                              <renderMultiMedia referencedObject="img_34009d15-bb1e-9b7e-e063-6294a90ae5e3"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 7:</content>
                           </td>
                           <td>Take the oral dosing syringe out of the medicine cup. Carefully turn the oral dosing syringe so that the tip is pointing up. Check to make sure that the amount of medicine in the oral dosing syringe lines up with the amount of mixture prescribed by your doctor (see Figure F).</td>
                           <td>
                              <renderMultiMedia referencedObject="img_3400ae9f-dda3-add1-e063-6394a90ac46d"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 8:</content>
                           </td>
                           <td>Place the tip of the oral dosing syringe into your baby’s mouth. Point the tip of the oral dosing syringe toward either cheek (see Figure G). Push on the plunger slowly, a small amount at a time, until all of the mixture in the oral dosing syringe is given.</td>
                           <td>
                              <renderMultiMedia referencedObject="img_3401f966-2fd5-37d1-e063-6394a90ad97a"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 9:</content>
                           </td>
                           <td>Throw away any remaining mixture. Remove the plunger from the barrel of the oral dosing syringe. Wash the oral dosing syringe and medicine cup with warm water and air dry. When the oral dosing syringe is dry, put the plunger back into the barrel. Store the oral dosing syringe and medicine cup for the next use.</td>
                           <td/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">How should I store ZELVYSIA ?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Store Zelvysia at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Protect from moisture.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep Zelvysia and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Aucta Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Piscataway, NJ 08854</paragraph>
                  <paragraph>Revised: 01/2025</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="img_34008ab2-335a-8f63-e063-6294a90a40d9">
                     <text>fig-a</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ins-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_34008ab2-335c-8f63-e063-6294a90a40d9">
                     <text>fig-b</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ins-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_3400a86f-2d9f-a1da-e063-6294a90a03bd">
                     <text>fig-c</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ins-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_3400af6f-1c5c-ace4-e063-6394a90aa473">
                     <text>fig-d</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ins-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_34009d15-bb1e-9b7e-e063-6294a90ae5e3">
                     <text>fig-e</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ins-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_3400ae9f-dda3-add1-e063-6394a90ac46d">
                     <text>fig-f</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ins-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_3401f966-2fd5-37d1-e063-6394a90ad97a">
                     <text>fig-g</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ins-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_34059a49-84fc-48cc-e063-6294a90a0fbc">
               <id root="3405b055-154b-eafd-e063-6394a90affac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>100 MG POWDER FOR ORAL SOLUTION PACKET</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_340597f8-c39e-ce72-e063-6394a90a5e1b"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="img_340597f8-c39e-ce72-e063-6394a90a5e1b">
                     <text>foil-100mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zelvysia-foil-100mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_38301bec-a691-41fb-809b-cd1a132a5248">
               <id root="3405b055-1549-eafd-e063-6394a90affac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>100 MG POWDER FOR ORAL SOLUTION CARTON</title>
               <text>
                  <paragraph>NDC 73289-0070-2</paragraph>
                  <paragraph>Zelvysia 
  <sup>TM</sup>
                  </paragraph>
                  <paragraph>(sapropterin dihydrochloride)</paragraph>
                  <paragraph>Powder for Oral Solution</paragraph>
                  <paragraph>100 mg*</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>30 individual packets per carton</paragraph>
                  <paragraph>Aucta</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3400f5f0-4b4c-c751-e063-6394a90af083"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="img_3400f5f0-4b4c-c751-e063-6394a90af083">
                     <text>carton-100mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zelvysia-carton-100mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_3405876a-d926-371b-e063-6294a90a17bd">
               <id root="3405b14d-8268-4d1d-e063-6294a90a12f9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>500 MG POWDER FOR ORAL SOLUTION PACKET</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3405976f-865d-cde6-e063-6394a90a24b7"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="img_3405976f-865d-cde6-e063-6394a90a24b7">
                     <text>foil-500mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zelvysia-foil-500mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_35a3494b-b0ef-4ccb-b6c5-2a3080a9c565">
               <id root="340597f8-c3a2-ce72-e063-6394a90a5e1b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>500 MG POWDER FOR ORAL SOLUTION CARTON</title>
               <text>
                  <paragraph>NDC 73289-0071-2</paragraph>
                  <paragraph>Zelvysia 
  <sup>TM</sup>
                  </paragraph>
                  <paragraph>(sapropterin dihydrochloride)</paragraph>
                  <paragraph>Powder for Oral Solution</paragraph>
                  <paragraph>500 mg* per single use packet</paragraph>
                  <paragraph>* Equivalent to 384 mg of sapropterin</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>30 individual packets per carton</paragraph>
                  <paragraph>Aucta</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3400f84d-8d38-da35-e063-6294a90a824d"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="img_3400f84d-8d38-da35-e063-6294a90a824d">
                     <text>carton-500mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zelvysia-carton-500mg.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>